Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX
17 Setembro 2019 - 07:45AM
Business Wire
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage
biopharmaceutical company developing multifunctional
biotherapeutics, announced that Lota Zoth has been appointed as its
Chair of the Board of Directors. Ms. Zoth succeeds Nick Bedford,
who has retired from his functions as Chair and Board member. Mr.
Bedford served as Board Chair since September 2004.
“Lota has provided valuable insights and a wealth of experience
as a member of Zymeworks’ Board since 2016 and we are pleased to
welcome her as our new Chair as we further advance our lead
clinical assets towards commercialization,” said Ali Tehrani,
Ph.D., Zymeworks’ President & CEO. “On behalf of the Board and
the executive team, I thank Nick for his contributions to
Zymeworks. He has been instrumental to our success over the past
fifteen years, particularly through the Company’s IPO in 2017.”
Ms. Zoth served as Chief Financial Officer of MedImmune prior to
the acquisition by AstraZeneca in 2007, and currently serves on the
boards of several biopharmaceutical companies, including Inovio
Pharmaceuticals, Inc., NewLink Genetics Corporation, and Spark
Therapeutics, Inc. Ms. Zoth also served as Chair of the Board of
Directors of Aeras, a biopharmaceutical product development partner
funded by the Bill & Melinda Gates Foundation.
Zymeworks has also made a strategic decision to voluntarily
delist its common shares from the Toronto Stock Exchange (TSX) in
Canada, which is currently anticipated to occur on or around
October 1, 2019. Zymeworks’ shares will continue to be traded on
the New York Stock Exchange (NYSE) under the symbol “ZYME” and
Canadian shareholders can continue to trade their shares on the
NYSE.
With active daily trading on the NYSE having accounted for the
vast majority of Zymeworks’ liquidity, the Company conducted a
thorough evaluation of its dual listing, considering such factors
as overall liquidity, the needs of its shareholders, costs,
regulatory compliance and complexity, and future capital raising
opportunities. In summary, the Company believes that the financial
and administrative costs associated with maintaining a dual listing
are no longer justified.
For answers to frequently asked questions about the voluntary
delisting, please visit the FAQ section of Zymeworks’ website at
https://ir.zymeworks.com/FAQs.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody
currently in Phase 2 clinical development. Zymeworks’ second
clinical candidate, ZW49, is a bispecific antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of ZW25 with Zymeworks’ proprietary
ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep
preclinical pipeline in immuno-oncology and other therapeutic
areas. In addition, its therapeutic platforms are being leveraged
through strategic partnerships with nine biopharmaceutical
companies. For more information, visit www.zymeworks.com.
Cautionary Note Regarding Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this news release include
statements that relate to expected delisting of the Company’s
shares from the TSX, the continued listing of its shares on the
NYSE, Canadian shareholders’ continued ability to trade their
shares on the NYSE, and other information that is not historical
information. When used herein, words such as “believe”, “will”,
“continue”, “anticipate”, and similar expressions are intended to
identify forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Zymeworks may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various factors, including, without limitation, market
conditions and the factors described under “Risk Factors” in
Zymeworks’ Quarterly Report on Form 10-Q for the three month period
ended June 30, 2019 (a copy of which may be obtained at www.sec.gov
and www.sedar.com). Consequently, forward-looking statements should
be regarded solely as Zymeworks’ current plans, estimates and
beliefs. You should not place undue reliance on forward-looking
statements. Zymeworks cannot guarantee future results, events,
levels of activity, performance or achievements. Zymeworks does not
undertake and specifically declines any obligation to update,
republish, or revise any forward-looking statements to reflect new
information, future events or circumstances, or to reflect the
occurrences of unanticipated events, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917005140/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Kavita Shah, Ph.D. (604) 678-1388
info@zymeworks.com
Zymeworks (NYSE:ZYME)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Zymeworks (NYSE:ZYME)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024